Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | ASPEN-05 preliminary data: evorpacept plus azacitidine and venetoclax in patients with AML

In this video, Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the important role of CD47 as a target in myeloid malignancies, highlighting agents such as magrolimab and evorpacept. Dr Erba outlines preliminary data from the Phase Ia dose escalation part of the ASPEN-05 study (NCT04755244), which is evaluating the safety and tolerability of evorpacept administered in combination with standard venetoclax and azacitidine in patients with acute myeloid leukemia (AML). Preliminary results have shown that the addition of evorpacept to standard dose venetoclax and azacitidine is well tolerated, with some patients already demonstrating peripheral blood blast clearance. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

ImmunoGen: Consultancy, Research Funding; Incyte: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; MacroGenics: Consultancy, Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Covance (Abbvie): Consultancy, Other: Independent Review Committee, Research Funding; Janssen Oncology: Consultancy; Trillium Therapeutics: Consultancy; Takeda: Consultancy; Kura Oncology: Consultancy, Research Funding; Forma Therapeutics: Research Funding; Gilead/Forty Seven: Research Funding; PTC therapeutics: Research Funding; ALX Oncology: Research Funding; Pfizer: Consultancy; Glycomimetics: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Celgene: Consultancy, Other, Speakers Bureau; Astellas Pharma: Consultancy; Amgen: Consultancy, Research Funding; Agios: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.